Published in J Chronic Dis on July 01, 1977
Variable Selection for Qualitative Interactions. Stat Methodol (2011) 1.52
Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol (1982) 1.23
The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS One (2014) 1.22
Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate. J Biopharm Stat (2011) 1.16
Estimation of treatment policies based on functional predictors. Stat Sin (2014) 0.96
Treatment Heterogeneity and Individual Qualitative Interaction. Am Stat (2012) 0.93
Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes. Clin Trials (2014) 0.80
Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. PLoS One (2017) 0.75
Statistical Methods for Establishing Personalized Treatment Rules in Oncology. Biomed Res Int (2015) 0.75
University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion). Clin Trials (2015) 0.75
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol (1985) 11.38
The ecological fallacy. Am J Epidemiol (1988) 6.38
Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med (1976) 5.86
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer (1973) 2.91
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer (1979) 2.67
Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst (2001) 2.43
A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol (1988) 2.20
Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl (1995) 1.83
Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer (1970) 1.82
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep (1983) 1.81
Why data bases should not replace randomized clinical trials. Biometrics (1980) 1.81
Aspects of statistical design for the Community Intervention Trial for Smoking Cessation (COMMIT). Control Clin Trials (1992) 1.58
Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer (1970) 1.58
Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology (1973) 1.53
The dietary fat--breast cancer hypothesis is alive. JAMA (1989) 1.48
Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer (1972) 1.38
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr (1988) 1.38
Decreased helper T lymphocytes in homosexual men. I. Sexual contact in high-incidence areas for the acquired immunodeficiency syndrome. Am J Epidemiol (1985) 1.37
Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med (1985) 1.32
Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology (1990) 1.32
Assessing the gain in efficiency due to matching in a community intervention study. Stat Med (1990) 1.30
How many controls? J Chronic Dis (1976) 1.19
Overadjustment in case-control studies. Am J Epidemiol (1980) 1.16
Tests for homogeneity of effect in an epidemiologic investigation. Am J Epidemiol (1977) 1.16
Factorial designs for randomized clinical trials. Cancer Treat Rep (1985) 1.14
Interplay between design and analysis for behavioral intervention trials with community as the unit of randomization. Am J Epidemiol (1995) 1.13
Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. N Engl J Med (1978) 1.11
Assessing apparent treatment--covariate interactions in randomized clinical trials. Stat Med (1985) 1.07
The choice of treatment for cancer patients based on covariate information. Bull Cancer (1980) 1.07
Geographic distribution of motor neuron disease and correlation with possible etiologic factors. Neurology (1983) 1.06
Estrogen predisposes to cholecystectomy but not to stones. Gastroenterology (1982) 1.01
The effect of stratified randomization on size and power of statistical tests in clinical trials. J Chronic Dis (1978) 0.97
Testing hypotheses in case-control studies--equivalence of Mantel-Haenszel statistics and logit score tests. Biometrics (1979) 0.97
Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer (1979) 0.96
The efficiency of the matched-pairs design of the Community Intervention Trial for Smoking Cessation (COMMIT). Control Clin Trials (1997) 0.95
Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med (1984) 0.95
A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. Biometrics (1984) 0.94
Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up. Scand J Urol Nephrol Suppl (1988) 0.94
Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med (1972) 0.94
A proposal for registering clinical trials. Control Clin Trials (1988) 0.92
Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol (1972) 0.91
The distribution of 65zinc in the prostate and other organs in control, castrated, and hypophysectomized rats. Invest Urol (1969) 0.90
Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J (1977) 0.88
Decreased helper T lymphocytes in homosexual men. II. Sexual practices. Am J Epidemiol (1985) 0.88
Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep (1983) 0.88
Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. Cancer Treat Rep (1979) 0.88
Some interrelationships among the regression coefficient estimates arising in a class of models appropriate to response-time data. Biometrics (1975) 0.88
Carcinoma of prostate. Correlation between radiologic quantitation of metastases and patient survival. Urology (1975) 0.86
Cancer of the prostate in men less than 50 years old: an analysis of 51 cases. J Urol (1969) 0.85
VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urological Research Group. Urology (1981) 0.84
Prognostic variables in mycosis fungoides. Cancer (1981) 0.83
Dependent competing risks and the latent-failure model. Biometrics (1988) 0.82
Quantitative radiology for staging and prognosis of patients with advanced prostatic carcinoma. Correlations with other pretreatment characteristics. Urology (1979) 0.81
Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. J Urol (1972) 0.80
Community Intervention Trial for Smoking Cessation (COMMIT): changes in community attitudes toward cigarette smoking. Health Educ Res (1998) 0.80
Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An extramural analysis. Cancer (1984) 0.80
Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer. N Engl J Med (1974) 0.79
A Voluntary Smokers' Registry: Characteristics of joiners and non-joiners in the Community Intervention Trial for Smoking Cessation (COMMIT). Am J Public Health (1998) 0.79
VACURG studies of post-prostatectomy survival. Scand J Urol Nephrol Suppl (1980) 0.79
Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer (1976) 0.78
Screening geographic areas for unusual survival experience or stage at diagnosis with application to breast and colon cancer. J Natl Cancer Inst (1985) 0.78
An evaluation of rectal mucosal proliferation measure variability sources in the polyp prevention trial: can we detect informative differences among individuals' proliferation measures amid the noise? Cancer Epidemiol Biomarkers Prev (1998) 0.78
Sound advice for conducting clinical trials. N Engl J Med (1977) 0.78
Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol (1973) 0.77
Errors-in-variables workshop. Stat Med (1989) 0.77
Preliminary studies of histologic prognosis in cancer of the prostate. Cancer Treat Rep (1977) 0.76
Does reserpine increase prolactin and exacerbate cancer of prostate? Case control study. Urology (1973) 0.75
Measuring cell proliferation in the rectal mucosa. comparing bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) assays. J Clin Epidemiol (2000) 0.75
Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. Control Clin Trials (1989) 0.75
Applications of the Mantel-Haenszel statistic to the comparison of survival distributions. Biometrics (1977) 0.75
Letter: Benign prostatic hyperplasia and cancer of the prostate. Lancet (1975) 0.75
Grading prostate cancers. Urology (1983) 0.75
A computerized reference laboratory. Med Instrum (1979) 0.75
Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: reply to a commentary. Cancer Treat Rep (1985) 0.75
VACURG studies of conservative treatment. Scand J Urol Nephrol Suppl (1980) 0.75
Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer (1976) 0.75
An exponential model relating censored survival data and concomitant information for prostatic cancer patients. J Natl Cancer Inst (1974) 0.75
An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostatic cancer. J Chronic Dis (1973) 0.75
Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer (1978) 0.75
Quantification of the effects of preventive measures. IARC Sci Publ (1990) 0.75
Proper analysis of clinical trials for malignant glioma. Cancer Treat Rep (1981) 0.75
Predicting survival in terminal cancer. Br Med J (1973) 0.75
Letters: Rserpine and prostatic cancer. Urology (1975) 0.75
Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer. J Urol (1975) 0.75
Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group. J Neurooncol (1994) 0.75
The study of markers of biological effect in cancer prevention research trials. Int J Cancer (1992) 0.75